Avantor® enters into definitive agreement to divest clinical services business to audax private equity

Accelerates ongoing business transformation and sharpens avantor's strategic focus strengthens balance sheet with proceeds to be used for debt paydown radnor, pa. , aug. 16, 2024 /prnewswire/ -- avantor, inc. (nyse: avtr), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the signing of a definitive agreement to divest its clinical services business, including kitting, biorepository, and related equipment and ancillaries (collectively "clinical services"), to audax private equity ("audax") for a transaction value of approximately $650 million.
AVTR Ratings Summary
AVTR Quant Ranking